Aglaia BioMedical Ventures B.V.

Overview

Aglaia BioMedical Ventures B.V. is a Dutch venture capital firm specializing in early-stage investments in the biomedical sector, focusing on oncology. The firm is based in Bilthoven, Utrecht, Netherlands, and was founded in 2003 by Mark Krul. Aglaia is dedicated to translating high-potential research into commercially and clinically successful products, emphasizing impact investing that combines financial and social returns. The firm's investment strategy involves selecting and maturing early-stage breakthrough inventions in the oncology field. Aglaia typically invests in seed, Series A, and Series B funding rounds, with investment sizes ranging from $500,000 to $10 million. The firm has a hands-on approach, actively participating in the strategic and operational processes of its portfolio companies to de-risk and mature them up to a level where they become attractive candidates for licensing, acquisition, or IPO. Aglaia's portfolio includes companies such as Sapreme Technologies, Macrophage Pharma, Cristal Therapeutics, Inthera Bioscience, InteRNA Technologies, and MIMETAS. The firm has been involved in the development of more than 100 oncology products, demonstrating its commitment to advancing healthcare solutions through cutting-edge technologies and strategic investments in the life sciences sector.

Investment Focus

• Early-stage oncology drug development
• Disruptive science with the potential to transform cancer diagnosis and therapy
• Sustainable technological advantage
• Above average business potential
• Sound intellectual property protection or potential for patenting
• Clearly definable milestones for development
• Scientist's commitment and dedication
• Foreseeable exit potential

Portfolio Companies